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linguistic differences between China and North America or Western Europe where 
PROs tend to be developed. The objective of this study was to identify some of the 
linguistic and cultural differences between English and Mandarin as well as cultural 
differences between North America and Western Europe and China. METHODS: Five 
questionnaires relating to varied health states were reviewed and the cultural and lin-
guistic issues arising during different stages of the translation process were examined. 
RESULTS: Numerous cultural and linguistic issues became apparent throughout the 
review, including: 1)Mandarin does not employ superlatives so “the worst” was 
translated as “extremely bad”; 2)some patients did not understand how to complete 
a VAS although the words themselves were clear; 3) there is no speciﬁc beneﬁt of 
“disability compensation” in China—this is a general beneﬁt which can include pen-
sions; 4) Private clinics where respondents receive acupuncture and massage are very 
common in China so additional categories had to be added to a resource utilisation 
measure; 5) in Mandarin questions cannot begin with “how often;” instead they are 
phrased “does it often”; 6) with response options such as “never”, “sometimes”, 
appropriate responses can still be chosen; and 6) Low levels of obesity in China made 
recruitment for the linguistic validation of an obesity measure difﬁcult. CONCLU-
SIONS: An increasing number of clinical trials take place in China. The issues raised 
above show some of the linguistic differences between English and Mandarin, and 
cultural differences between Western Europe / North America and China. These and 
other issues are important to consider when selecting, developing and translating 
measures for use in China.
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OBJECTIVES: The purpose of this study was to explore the incremental cost-effective-
ness ratio (ICER) ranges of variant health interventions. METHODS: We performed 
the systematic review of cost-effectiveness studies about health interventions. Com-
prehensive literature review was conducted using MEDLINE and EMBASE with a 
publication date before March 24, 2009. We selected literatures based on the follow-
ing criteria; 1) written in the English and Korean languages; 2) contained information 
on interventions relevant to diseases or health problems; 3) reported cost per year of 
life saved or contained sufﬁcient information to calculate this ratio; 4) study methodol-
ogy related to economic evaluations such as cost-utility analysis (CUA) and cost-
effectiveness analysis (CEA), and 5) contained information whether the health 
intervention is cost-effective or not. We calculated the mean of reported ICER of major 
therapeutic area and major countries from all selected literature and extracted implicit 
ICER threshold based on the author’s conclusion about cost-effectiveness. The value 
of ICER in each literature was converted to 2008 value reﬂecting exchange rate and 
price index. RESULTS: A total of 3662 articles were originally identiﬁed from the 
planned searching strategy. 1466 among them were ﬁnally included to calculate ICER 
range after abstract review and/or full text review. Two independent reviewers worked 
to select relevant articles and extract data. Mean incremental cost per Quality-
adjusted-life-years-gained or Life-years-gained were US$130,514, US$25,446, 
US$30,448, US$70,420 for cancer, cardiovascular diseases, endocrine disease, and 
musculoskeletal disease, respectively. The ICER according to countries were also 
varied a lot. If we see the author’s judgment on cost-effectiveness, some interventions 
were recommended as cost-effective even in the case ICER were approximately 
US$80,000, US$75,000, US$200,000 for UK, Canada, and USA. CONCLUSIONS: 
The judgment on cost-effective interventions could be different according to countries 
and disease. It tends to have higher ICER in severe disease and in developed 
countries.
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OBJECTIVES: The National Institute for Health and Clinical Excellence (NICE) has 
expressed a preference for the EQ-5D in cost-effectiveness analyses. Directly eliciting 
EQ-5D scores for speciﬁc disease states can be cumbersome and expensive. Use of 
disparate sources of utility scores by different researchers introduces variability and 
potential bias. Developing an “off-the-shelf” catalogue provides easily accessible EQ-
5D scores from a single-source general population. The current study aims to develop 
a catalogue of EQ-5D scores for chronic conditions using U.K. preferences. 
METHODS: The Medical Expenditure Panel Survey (MEPS), a general population 
survey in the U.S., was pooled (2000, 2001, 2002 and 2003) to create a sample of 
79,524 adults with valid EQ-5D responses. The EQ-5D was administered via a paper 
and pencil self-administered questionnaire (SAQ) to adults q 18 years. UK tariffs for 
the EQ-5D (Dolan) were applied to questionnaire responses. Chronic conditions were 
classiﬁed by ICD-9 codes and Clinical Classiﬁcation Category (CCC) codes. Ordinary 
least squares (OLS), Tobit, and censored least absolute deviations (CLAD) regression 
methods were used to estimate the marginal disutility of each condition controlling 
for age, comorbidity, gender, race, ethnicity, income and education. RESULTS: A 
catalogue of several hundred statistically signiﬁcant marginal disutility (EQ-5D) scores 
for each chronic ICD-9 and CCC code are presented and compared. Marginal disutili-
ties for each condition represent the isolated impact of the condition after controlling 
for comorbidity and covariates. CONCLUSIONS: This research provides a catalogue 
of “off-the-shelf” UK-based preference scores for the EQ-5D based on a single-source 
general population survey. Scores and marginal disutilities for a wide variety of 
chronic ICD-9 and CCC codes can be used to estimate QALYs in cost-effectiveness 
analyses in the UK. Although the preference function was derived from a U.K. popula-
tion sample, there are limitations associated with using a US survey to develop the 
condition-speciﬁc questionnaire responses.
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OBJECTIVES: Time trade-off (TTO) utilities are traditionally elicited through face-
to-face interviews, but these may be costly and time-consuming. We recruited a sample 
of restless-legs syndrome (RLS) sufferers using an online panel and administered an 
online version of TTO. METHODS: Members of a UK online marketing research 
panel were invited to participate, subject to conﬁrmation of RLS diagnosis. The 
recruitment target was a minimum of 50 subjects in each of 4 severity categories based 
on the International Restless Legs Syndrome (IRLS) score. The TTO interface was 
adapted from a widely used, validated protocol for face-to-face administration. We 
explored associations between self-rated health according to IRLS, EQ-5D (UK tariff) 
and the online TTO. RESULTS: Over 15 days, 287 eligible participants (57, 90, 90 
and 50 in mild, moderate, severe and very severe categories respectively) were 
recruited. Mean EQ-5D utilities by severity category were 0.80, 0.67, 0.51 and 0.29. 
275 participants agreed to complete the TTO. Twenty-four percent were unwilling to 
sacriﬁce any life expectancy in their current state of health although they preferred a 
life in full health for a similar duration. Mean TTO utilities by severity category were 
0.83, 0.82, 0.75 and 0.56. The correlation between EQ-5D and TTO utilities was 
0.354 (p  0.0001). TTO utilities were associated with EQ-5D utilities independently 
of IRLS score. Neither EQ-5D nor TTO utilities were signiﬁcantly associated with age 
or gender, after controlling for IRLS score. Social class was signiﬁcantly associated 
with EQ-5D, but not with TTO. CONCLUSIONS: Online recruitment enabled rapid 
recruitment of subjects with RLS. Correlations between TTO utilities and other vari-
ables were consistent with expectations, but the number of non-traders seemed high. 
Comparative studies with face-to-face TTO would be desirable, as the online approach 
seems an attractive solution to allow primary utility elicitation when time or cost 
constraints preclude a face-to-face survey.
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In ﬁrst EQ-5D valuation studies based on time-trade-off (TTO) respondents valued 
13 health states. OBJECTIVES: To evaluate the possible bias resulting from expanding 
the TTO experiment to 23 states per respondent. METHODS: In Polish EQ-5D valu-
ation study, 7351 TTO valuations from 321 respondents were available before exclu-
sions. First, we tested whether the mean valuation for each health state differed when 
it was valued in the middle of the experiment (6th-17th state) or at the end of the 
experiment (18th-23rd state). A series of t-tests for the equality of means and equality 
of variances was performed for each health state separately. To control for the multiple 
hypotheses testing the Hölm-Bonferroni correction was used. Moreover, to test the 
stability of regression coefﬁcients within TTO experiment, Chow tests were per-
formed: with the whole sample divided into two or three subgroups. In both cases the 
basic model with no interaction terms was used. RESULTS: The comparison of health 
state values when assigned during the middle of the experiment or at the end showed 
no statistically signiﬁcant differences neither in mean nor in variance (the smallest P-
values for means and variances comparison were equal to 0.0161 and 0.0060 respec-
tively, with Hölm-Bonferroni threshold of 0.0023). Regression coefﬁcients of two 
parsimonious models built on valuations 1st–17th (n  5009) or 18th–23rd (n  1760), 
did not differ signiﬁcantly in Chow test (p  0.5521). Similarly, regression coefﬁcients 
of three parsimonious models built on valuations 1st–5th (n  1461), 6th–17th (n  
3548) or 18th–23rd, did not differ (p  0.4334), neither. CONCLUSIONS: As we 
found no systematic change neither in mean, nor in variance, nor in model parameters 
due to TTO experiment extension, we believe there is no risk of a bias or efﬁciency 
decrease in the model estimation. The present study supports the use of more health 
states per respondent in TTO valuations than previously thought.
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OBJECTIVES: The majority of PRO measures are developed using a sequential rather 
than a cross-cultural approach and have been developed in the US and/or UK. When 
using these measures in multi-national trials, the assumption is made that the trans-
lated measure is acceptable for use in a multi-national trial, providing the translation 
